Gonadotrophin releasing hormone agonists for hirsutism references
* Bergfeld WF. Hirsutism in women. Effective therapy that is
safe for long-term use. Postgrad Med. 2000 Jun;107(7):93-4,
99-104.
* Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C.
Prospective randomized study comparing the long-acting gonadotropin-releasing
hormone agonist triptorelin, flutamide, and cyproterone acetate,
used in combination with an oral contraceptive, in the treatment
of hirsutism. Fertil Steril. 1999 Jan;71(1):122-8.
* Azziz R, Rittmaster RS, Fox LM, Bradley EL Jr, Potter HD,
Boots LR. Role of the ovary in the adrenal androgen excess of
hyperandrogenic women. Fertil Steril. 1998 May;69(5):851-9.
* Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist
therapy for hirsutism is as effective as high dose cyproterone
acetate but results in a longer remission. Hum Reprod. 1997
Apr;12(4):663-6.
* Acien P, Mauri M, Gutierrez M. Clinical and hormonal effects
of the combination gonadotrophin-releasing hormone agonist plus
oral contraceptive pills containing ethinyl-oestradiol (EE)
and cyproterone acetate (CPA) versus the EE-CPA pill alone on
polycystic ovarian disease-related hyperandrogenisms. Hum Reprod.
1997 Mar;12(3):423-9.
* Heiner JS, Greendale GA, Kawakami AK, Lapolt PS, Fisher M,
Young D, Judd HL. Comparison of a gonadotropin-releasing hormone
agonist and a low dose oral contraceptive given alone or together
in the treatment of hirsutism. J Clin Endocrinol Metab. 1995
Dec;80(12):3412-8.
* Carmina E, Stanczyk FZ, Gentzchein E, Lobo RA. Time-dependent
changes in serum 3 alpha-androstanediol glucuronide correlate
with hirsutism scores after ovarian suppression. Gynecol Endocrinol.
1995 Sep;9(3):215-20.
* Elkind-Hirsch KE, Anania C, Mack M, Malinak R. Combination
gonadotropin-releasing hormone agonist and oral contraceptive
therapy improves treatment of hirsute women with ovarian hyperandrogenism.
Fertil Steril. 1995 May;63(5):970-8.
* Carr BR, Breslau NA, Givens C, Byrd W, Barnett-Hamm C, Marshburn
PB. Oral contraceptive pills, gonadotropin-releasing hormone
agonists, or use in combination for treatment of hirsutism:
a clinical research center study. J Clin Endocrinol Metab. 1995
Apr;80(4):1169-78.
* Lemay A, Faure N. Sequential estrogen-progestin addition to
gonadotropin-releasing hormone agonist suppression for the chronic
treatment of ovarian hyperandrogenism: a pilot study. J Clin
Endocrinol Metab. 1994 Dec;79(6):1716-22.
* Tiitinen A, Simberg N, Stenman UH, Ylikorkala O. Estrogen
replacement does not potentiate gonadotropin-releasing hormone
agonist-induced androgen suppression in treatment of hirsutism.
J Clin Endocrinol Metab. 1994 Aug;79(2):447-51.
* Carmina E, Janni A, Lobo RA. Physiological estrogen replacement
may enhance the effectiveness of the gonadotropin-releasing
hormone agonist in the treatment of hirsutism. J Clin Endocrinol
Metab. 1994 Jan;78(1):126-30.
* Lee WL, Wang PH, Tseng HS, Lin HD, Yuan CC, Chao HT. Managing
a patient with presumed testosterone-secreting ovarian tumor.
Gynecol Oncol. 1999 Oct;75(1):175-7.
* Barnes RB, Ehrmann DA. Long-term suppression of testosterone
after treatment with a gonadotropin-releasing hormone agonist
in a woman with a presumed testosterone secreting ovarian tumor.
J Clin Endocrinol Metab. 1997 Jun;82(6):1746-8.
* Koroscil TM, Harter SB, Ouweleen J, Blauer KL. Use of a gonadotropin-releasing
hormone agonist in the evaluation of postmenopausal virilization
due to ovarian hyperthecosis. A case report. J Reprod Med. 1996
Apr;41(4):259-62.
* Falsetti L, Pasinetti E, Ceruti D. Gonadotropin-releasing
hormone agonist (GnRH-A) in hirsutism. Acta Eur Fertil. 1994
Sep-Oct;25(5):303-6.
* Goni M, Markussis V, Tolis G. Efficacy of chronic therapy
with the gonadotrophin releasing hormone agonist decapeptyl
in patients with polycystic ovary syndrome. Hum Reprod. 1994
Jun;9(6):1048-52.
* Falsetti L, Pasinetti E. Treatment of moderate and severe
hirsutism by gonadotropin-releasing hormone agonists in women
with polycystic ovary syndrome and idiopathic hirsutism. Fertil
Steril. 1994 May;61(5):817-22.
* Faloia E, Filipponi S, Mancini V, Morosini P, De Pirro R.
Treatment with a gonadotropin-releasing hormone agonist in acne
or idiopathic hirsutism. J Endocrinol Invest. 1993 Oct;16(9):675-7.
* Hodgen GD. Gonadotropin-releasing hormone agonists: emerging
modification of treatment regimens. Curr Opin Obstet Gynecol.
1991 Jun;3(3):352-7.
* Rittmaster RS. Differential suppression of testosterone and
estradiol in hirsute women with the superactive gonadotropin-releasing
hormone agonist leuprolide. J Clin Endocrinol Metab. 1988 Oct;67(4):651-5.
* Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with
a gonadotropin-releasing hormone agonist (nafarelin). J Clin
Endocrinol Metab. 1986 Oct;63(4):854-9.
* Steingold KA, Judd HL, Nieberg RK, Lu JK, Chang RJ. Treatment
of severe androgen excess due to ovarian hyperthecosis with
a long-acting gonadotropin-releasing hormone agonist. Am J Obstet
Gynecol. 1986 Jun;154(6):1241-8.
------------------------------------------------------------------------
Ketoconazole for hirsutism references
* Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli
B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized
trial comparing low dose flutamide, finasteride, ketoconazole,
and cyproterone acetate-estrogen regimens in the treatment of
hirsutism. J Clin Endocrinol Metab. 1999 Apr;84(4):1304-10.
* Isik AZ, Gokmen O, Zeyneloglu HB, Senoz S, Zorlu CG. Low dose
ketoconazole is an effective and a relatively safe alternative
in the treatment of hirsutism. Aust N Z J Obstet Gynaecol. 1996
Nov;36(4):487-9.
* Vidal-Puig AJ, Munoz-Torres M, Jodar-Gimeno E, Garcia-Calvente
CJ, Lardelli P, Ruiz-Requena ME, Escobar-Jimenez F. Ketoconazole
therapy: hormonal and clinical effects in non-tumoral hyperandrogenism.
Eur J Endocrinol. 1994 Apr;130(4):333-8.
* Akalin S. Effects of ketoconazole in hirsute women. Acta Endocrinol
(Copenh). 1991 Jan;124(1):19-22.
* Conget JI, Halperin I, Ferrer J, Gonzalez-Clemente JM, Martinez-Osaba
MJ, Vilardell E. Evaluation of clinical and hormonal effects
in hirsute women treated with ketoconazole. J Endocrinol Invest.
1990 Dec;13(11):867-70.
* Venturoli S, Fabbri R, Dal Prato L, Mantovani B, Capelli M,
Magrini O, Flamigni C. Ketoconazole therapy for women with acne
and/or hirsutism. J Clin Endocrinol Metab. 1990 Aug;71(2):335-9.
* Cedeno J, Mendoza SG, Velazquez E, Nucete H, Speirs J, Glueck
CJ. Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins,
and apolipoproteins in hyperandrogenic women. Metabolism. 1990
May;39(5):511-7.
* Sonino N, Scaroni C, Biason A, Boscaro M, Mantero F. Low-dose
ketoconazole treatment in hirsute women. J Endocrinol Invest.
1990 Jan;13(1):35-40.
* Weber MM, Luppa P, Engelhardt D. Inhibition of human adrenal
androgen secretion by ketoconazole. Klin Wochenschr. 1989 Jul
17;67(14):707-12.
* Martikainen H, Heikkinen J, Ruokonen A, Kauppila A. Hormonal
and clinical effects of ketoconazole in hirsute women. J Clin
Endocrinol Metab. 1988 May;66(5):987-91.
* Or M, Akbatur H, Hasanerisoglu B, Bilgihan K, Cakir N. Ketoconazole
induced papilledema. Acta Ophthalmol (Copenh). 1993 Apr;71(2):270-2.
* Sonino N. Current trends in the endocrine use of ketoconazole.
J Endocrinol Invest. 1988 Nov;11(10):741-4.
* De Pedrini P, Tommaselli A, Spano G, Montemurro G. Clinical
and hormonal effects of ketoconazole on hirsutism in women.
Int J Tissue React. 1988;10(3):193-8.
* Sonino N. The endocrine effects of ketoconazole. J Endocrinol
Invest. 1986 Aug;9(4):341-7.
* Carvalho D, Pignatelli D, Resende C. Ketoconazole for hirsutism.
Lancet. 1985 Sep 7;2(8454):560.
------------------------------------------------------------------------
Spironolactone for hirsutism references
* Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone
as a single agent for long-term therapy of hirsute patients.
Clin Endocrinol (Oxf). 2000 May;52(5):587-94.
* Erenus M, Yucelten D, Durmusoglu F, Gurbuz O. Comparison of
finasteride versus spironolactone in the treatment of idiopathic
hirsutism. Fertil Steril. 1997 Dec;68(6):1000-3.
* Erenus M, Yucelten D, Gurbuz O, Durmusoglu F, Pekin S. Comparison
of spironolactone-oral contraceptive versus cyproterone acetate-estrogen
regimens in the treatment of hirsutism. Fertil Steril. 1996
Aug;66(2):216-9.
* Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA.
A prospective randomized trial comparing finasteride to spironolactone
in the treatment of hirsute women. J Clin Endocrinol Metab.
1995 Jan;80(1):233-8.
* Crosby PD, Rittmaster RS. Predictors of clinical response
in hirsute women treated with spironolactone. Fertil Steril.
1991 Jun;55(6):1076-81.
* Prezelj J, Kocijancic A, Andolsek L. Dexamethasone and spironolactone
in the treatment of non-tumorous hyperandrogenism. Gynecol Endocrinol.
1989 Dec;3(4):281-8.
* Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Spironolactone
is an effective and well tolerated systemic antiandrogen therapy
for Hirsute women. J Clin Endocrinol Metab. 1989 May;68(5):966-70.
* Helfer EL, Miller JL, Rose LI. Side-effects of spironolactone
therapy in the hirsute woman. J Clin Endocrinol Metab. 1988
Jan;66(1):208-11.
* Lunde O, Djoseland O. A comparative study of Aldactone and
Diane in the treatment of hirsutism. J Steroid Biochem. 1987
Aug;28(2):161-5.
* Ylostalo P, Heikkinen J, Kauppila A, Pakarinen A, Jarvinen
PA. Low-dose spironolactone in the treatment of female hirsutism.
Int J Fertil. 1987 Jan-Feb;32(1):41-5.
* Pittaway DE, Maxson WS, Wentz AC. Spironolactone in combination
drug therapy for unresponsive hirsutism. Fertil Steril. 1985
Jun;43(6):878-82.
* Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism
with spironolactone. JAMA. 1982 Mar 5;247(9):1295-8.
* Marcondes JA, Minanni SL, Luthold WW, Lerario AC, Nery M,
Mendonca BB, Wajchenberg BL, Kirschner MA. The effects of spironolactone
on testosterone fractions and sex-hormone binding globulin binding
capacity in hirsute women. J Endocrinol Invest. 1995 Jun;18(6):431-5.
* McMullen GR, Van Herle AJ. Hirsutism and the effectiveness
of spironolactone in its management. J Endocrinol Invest. 1993
Dec;16(11):925-32.
* Wild RA, Demers LM, Applebaum-Bowden D, Lenker R. Hirsutism:
metabolic effects of two commonly used oral contraceptives and
spironolactone. Contraception. 1991 Aug;44(2):113-24.
* Cumming DC. Use of spironolactone in treatment of hirsutism.
Cleve Clin J Med. 1990 May;57(3):285-7.
* Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J
Dermatol. 1988 May;118(5):687-91.
* Board JA, Rosenberg SM, Smeltzer JS. Spironolactone and estrogen-progestin
therapy for hirsutism. South Med J. 1987 Apr;80(4):483-6.
* Evans DJ, Burke CW. Spironolactone in the treatment of idiopathic
hirsutism and the polycystic ovary syndrome. J R Soc Med. 1986
Aug;79(8):451-3.
* Tremblay RR. Treatment of hirsutism with spironolactone. Clin
Endocrinol Metab. 1986 May;15(2):363-71.
* Chapman MG, Katz M, Dowsett M, Hague W, Jeffcoate SL, Dewhurst
CJ. Spironolactone in the treatment of hirsutism. Acta Obstet
Gynecol Scand. 1986;65(4):349-50.
* Chapman MG, Dowsett M, Dewhurst CJ, Jeffcoate SL. Spironolactone
in combination with an oral contraceptive: an alternative treatment
for hirsutism. Br J Obstet Gynaecol. 1985 Sep;92(9):983-5.
* Thomas AK, Slobodniuk R, Taft J, Cooper M, Montalto J, Jerums
G. The treatment of hirsutism: experience with cyproterone acetate
and spironolactone. Australas J Dermatol. 1985 Apr;26(1):19-24.
* Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects
of two doses of spironolactone on serum androgens and anagen
hair in hirsute women. Fertil Steril. 1985 Feb;43(2):200-5.
* Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi
RF, Molinatti GM. Antiandrogenic properties of spironolactone.
Clinical trial in the management of female hirsutism. J Endocrinol
Invest. 1983 Feb;6(1):23-7.
* Ross HD. Tumorigenic aspect of spironolactone. West J Med.
1981 Sep;135(3):244.
* Shapiro G, Evron S. A novel use of spironolactone: treatment
of hirsutism. J Clin Endocrinol Metab. 1980 Sep;51(3):429-32.
* Ober KP, Hennessy JF. Spironolactone therapy for hirsutism
in a hyperandrogenic woman. Ann Intern Med. 1978 Nov;89(5 Pt
1):643-4.
------------------------------------------------------------------------
Cyproterone acetate for hirsutism references
* Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola
G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride
in the treatment of hirsutism. Fertil Steril. 2000 Apr;73(4):718-23.
* Yucelten D, Erenus M, Gurbuz O, Durmusoglu F. Recurrence rate
of hirsutism after 3 different antiandrogen therapies. J Am
Acad Dermatol. 1999 Jul;41(1):64-8.
* Pazos F, Escobar-Morreale HF, Balsa J, Sancho JM, Varela C.
Prospective randomized study comparing the long-acting gonadotropin-releasing
hormone agonist triptorelin, flutamide, and cyproterone acetate,
used in combination with an oral contraceptive, in the treatment
of hirsutism. Fertil Steril. 1999 Jan;71(1):122-8.
* Castelo-Branco C, Martinez de Osaba MJ, Pons F, Vanrell JA.
Effects on bone mass of two oral contraceptives containing ethinylestradiol
and cyproterone acetate or desogestrel: results of a 2-year
follow-up. Eur J Contracept Reprod Health Care. 1998 Jun;3(2):79-84.
* Sahin Y, Bayram F, Kelestimur F, Muderris I. Comparison of
cyproterone acetate plus ethinyl estradiol and finasteride in
the treatment of hirsutism. J Endocrinol Invest. 1998 Jun;21(6):348-52.
* Venturoli S, Ravaioli B, Bagnoli A, Colombo FM, Macrelli S,
Iadarola I, Vianello F, Mancini F, Flamigni C. Contraceptive
and therapeutic effectiveness of two low-dose ethinylestradiol
and cyproterone acetate regimens in the treatment of hirsute
patients. Eur J Contracept Reprod Health Care. 1998 Mar;3(1):29-33.
* Kelestimur F, Sahin Y. Comparison of Diane 35 and Diane 35
plus spironolactone in the treatment of hirsutism. Fertil Steril.
1998 Jan;69(1):66-9.
* Gokmen O, Senoz S, Gulekli B, Isik AZ. Comparison of four
different treatment regimes in hirsutism related to polycystic
ovary syndrome. Gynecol Endocrinol. 1996 Aug;10(4):249-55.
* Erenus M, Yucelten D, Gurbuz O, Durmusoglu F, Pekin S. Comparison
of spironolactone-oral contraceptive versus cyproterone acetate-estrogen
regimens in the treatment of hirsutism. Fertil Steril. 1996
Aug;66(2):216-9.
* van Wayjen RG, van den Ende A. Experience in the long-term
treatment of patients with hirsutism and/or acne with cyproterone
acetate-containing preparations: efficacy, metabolic and endocrine
effects. Exp Clin Endocrinol Diabetes. 1995;103(4):241-51.
* Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone
acetate for severe hirsutism: results of a double-blind dose-ranging
study. Clin Endocrinol (Oxf). 1991 Jul;35(1):5-10.
* Adamopoulos DA, Kampyli S, Georgiacodis F, Kapolla N, Abrahamian-Michalakis
A. Effects of antiandrogen-estrogen treatment on sexual and
endocrine parameters in hirsute women. Arch Sex Behav. 1988
Oct;17(5):421-9.
* Belisle S, Love EJ. Clinical efficacy and safety of cyproterone
acetate in severe hirsutism: results of a multicentered Canadian
study. Fertil Steril. 1986 Dec;46(6):1015-20.
* Galindo PA, Borja J, Feo F, Gomez E, Chamorro R, Encinas C,
Garcia R. Fixed drug eruption caused by cyproterone acetate.
Allergy. 1998 Aug;53(8):813.
* Similowski T, Orcel B, Derenne JP.CD8+ lymphocytic pneumonitis
in a patient receiving cyproterone acetate. South Med J. 1997
Oct;90(10):1048-9.
* Hammerstein J, Moltz L, Schwartz U. Antiandrogens in the treatment
of acne and hirsutism. J Steroid Biochem. 1983 Jul;19(1B):591-7.
* Hammerstein J, Cupceancu B. The treatment of hissutism with
cyproterone acetate. Ger Med Mon. 1969 Dec;14(12):599-602.
* Hammerstein J, Cupceancu B. [Management of hirsutism using
cyproterone acetate]. Dtsch Med Wochenschr. 1969 Apr 18;94(16):829-34.
------------------------------------------------------------------------
Flutamide for hirsutism references
* Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism,
hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism
in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol
Metab. 2000 Sep;85(9):3251-5.
* Muderris II, Bayram F, Guven M. Treatment of hirsutism with
lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol. 2000
Feb;14(1):38-41.
* Muderris II, Bayram F, Guven M. A prospective, randomized
trial comparing flutamide (250 mg/d) and finasteride (5 mg/d)
in the treatment of hirsutism. Fertil Steril. 2000 May;73(5):984-7.
* Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone
F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone,
flutamide, and finasteride efficacy in the treatment of hirsutism:
a randomized, double blind, placebo-controlled trial. J Clin
Endocrinol Metab. 2000 Jan;85(1):89-94.
* Paoletti AM, Cagnacci A, Orru M, Ajossa S, Guerriero S, Melis
GB. Treatment with flutamide improves hyperinsulinemia in women
with idiopathic hirsutism. Fertil Steril. 1999 Sep;72(3):448-53.
* Yucelten D, Erenus M, Gurbuz O, Durmusoglu F. Recurrence rate
of hirsutism after 3 different antiandrogen therapies. J Am
Acad Dermatol. 1999 Jul;41(1):64-8.
* Muderris II, Bayram F. Clinical efficacy of lower dose flutamide
125 mg/day in the treatment of hirsutism. J Endocrinol Invest.
1999 Mar;22(3):165-8.
* Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli
B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized
trial comparing low dose flutamide, finasteride, ketoconazole,
and cyproterone acetate-estrogen regimens in the treatment of
hirsutism. J Clin Endocrinol Metab. 1999 Apr;84(4):1304-10.
* Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri
C, Tosi F, Muggeo M, Adami S. Spironolactone, but not flutamide,
administration prevents bone loss in hyperandrogenic women treated
with gonadotropin-releasing hormone agonist. J Clin Endocrinol
Metab. 1999 Apr;84(4):1250-4.
* De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G.
Hormonal effects of flutamide in young women with polycystic
ovary syndrome. J Clin Endocrinol Metab. 1998 Jan;83(1):99-102.
* Muderris II, Bayram F, Sahin Y, Kelestimur F. A comparison
between two doses of flutamide (250 mg/d and 500 mg/d) in the
treatment of hirsutism. Fertil Steril. 1997 Oct;68(4):644-7.
* Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos
P, Giannikos L. Comparison of flutamide and cyproterone acetate
in the treatment of hirsutism: a randomized controlled trial.
Gynecol Endocrinol. 1996 Apr;10(2):119-23.
* Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL,
Fraga E, Hidalgo F. Fulminant liver failure associated with
flutamide therapy for hirsutism. Lancet. 1999 Mar 20;353(9157):983.
* Falsetti L, De Fusco D, Eleftheriou G, Rosina B. Treatment
of hirsutism by finasteride and flutamide in women with polycystic
ovary syndrome. Gynecol Endocrinol. 1997 Aug;11(4):251-7.
* Muderris II, Bayram F, Sahin Y, Kelestimur F, Tutus A, Ayata
D. The efficacy of 250 mg/day flutamide in the treatment of
patients with hirsutism. Fertil Steril. 1996 Aug;66(2):220-2.
* Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol.
1996 Jan;155(1):209-12.
* Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy
J, Lemay A. Clinical efficacy and safety of low-dose flutamide
alone and combined with an oral contraceptive for the treatment
of idiopathic hirsutism. Clin Endocrinol (Oxf). 1995 Nov;43(5):575-82.
* Pucci E, Genazzani AD, Monzani F, Lippi F, Angelini F, Gargani
M, Barletta D, Luisi M, Genazzani AR. Prolonged treatment of
hirsutism with flutamide alone in patients affected by polycystic
ovary syndrome. Gynecol Endocrinol. 1995 Sep;9(3):221-8.
* Erenus M. Efficacy of flutamide versus spironolactone. Fertil
Steril. 1995 Mar;63(3):680.
* Ciotta L, Cianci A, Marletta E, Pisana L, Agliano A, Palumbo
G. Treatment of hirsutism with flutamide and a low-dosage oral
contraceptive in polycystic ovarian disease patients. Fertil
Steril. 1994 Dec;62(6):1129-35.
* Wysowski DK, Fourcroy JL. Safety of flutamide? Fertil Steril.
1994 Nov;62(5):1089-90.
* Cesur V, Kamel N, Uysal AR, Erdogan G, Baskal N. The use of
antiandrogen flutamide in the treatment of hirsutism. Endocr
J. 1994 Oct;41(5):573-7.
* Howe RS, Chow RP, Stevens CL. Use of flutamide for self-induced
androgen excess. A case report. J Reprod Med. 1994 Oct;39(10):838-40.
* Marugo M, Bernasconi D, Meozzi M, Del Monte P, Zino V, Primarolo
P, Badaracco B. The use of flutamide in the management of hirsutism.
J Endocrinol Invest. 1994 Mar;17(3):195-9.
* Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison
of flutamide and spironolactone in the treatment of hirsutism:
a randomized controlled trial. Fertil Steril. 1994 Feb;61(2):281-7.
* Wallace C, Lalor EA, Chik CL. Hepatotoxicity complicating
flutamide treatment of hirsutism. Ann Intern Med. 1993 Dec 1;119(11):1150.
* Grimaldi F, Proto G, Bertolissi F. Flutamide--effects and
side effects. Fertil Steril. 1993 Apr;59(4):937.
------------------------------------------------------------------------
Finasteride for hirsutism references
* Muderris II, Bayram F, Guven M. A prospective, randomized
trial comparing flutamide (250 mg/d) and finasteride (5 mg/d)
in the treatment of hirsutism. Fertil Steril. 2000 May;73(5):984-7.
* Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola
G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride
in the treatment of hirsutism. Fertil Steril. 2000 Apr;73(4):718-23.
* Petrone A, Civitillo RM, Galante L, Giannotti F, D'Anto V,
Rippa G, Tolino A. Usefulness of a 12-month treatment with finasteride
in idiophathic and polycystic ovary syndrome-associated hirsutism.
Clin Exp Obstet Gynecol. 1999;26(3-4):213-6.
* Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone
F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone,
flutamide, and finasteride efficacy in the treatment of hirsutism:
a randomized, double blind, placebo-controlled trial. J Clin
Endocrinol Metab. 2000 Jan;85(1):89-94.
* Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G.
Comparison of finasteride versus flutamide in the treatment
of hirsutism. Eur J Endocrinol. 1999 Oct;141(4):361-7.
* Bayram F, Muderris II, Sahin Y, Kelestimur F. Finasteride
treatment for one year in 35 hirsute patients. Exp Clin Endocrinol
Diabetes. 1999;107(3):195-7.
* Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli
B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized
trial comparing low dose flutamide, finasteride, ketoconazole,
and cyproterone acetate-estrogen regimens in the treatment of
hirsutism. J Clin Endocrinol Metab. 1999 Apr;84(4):1304-10.
* Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani AR. Treatment
of hirsutism: comparisons between different antiandrogens with
central and peripheral effects. Fertil Steril. 1999 Mar;71(3):445-51.
* Faloia E, Filipponi S, Mancini V, Di Marco S, Mantero F. Effect
of finasteride in idiopathic hirsutism. J Endocrinol Invest.
1998 Nov;21(10):694-8.
* Erenus M, Yucelten D, Durmusoglu F, Gurbuz O. Comparison of
finasteride versus spironolactone in the treatment of idiopathic
hirsutism. Fertil Steril. 1997 Dec;68(6):1000-3.
* Guarna A, Belle C, Machetti F, Occhiato EG, Payne AH, Cassiani
C, Comerci A, Danza G, De Bellis A, Dini S, Marrucci A, Serio
M. 19-nor-10-azasteroids: a novel class of inhibitors for human
steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
* Castello R, Tosi F, Perrone F, Negri C, Muggeo M, Moghetti
P. Outcome of long-term treatment with the 5 alpha-reductase
inhibitor finasteride in idiopathic hirsutism: clinical and
hormonal effects during a 1-year course of therapy and 1-year
follow-up. Fertil Steril. 1996 Nov;66(5):734-40.
* Tolino A, Petrone A, Sarnacchiaro F, Cirillo D, Ronsini S,
Lombardi G, Nappi C. s Finasteride in the treatment of hirsutism:
new therapeutic perspectives. Fertil Steril. 1996 Jul;66(1):61-5.
* Mestayer C, Berthaut I, Portois MC, Wright F, Kuttenn F, Mowszowicz
I, Mauvais-Jarvis P. Predominant expression of 5 alpha-reductase
type 1 in pubic skin from normal subjects and hirsute patients.
J Clin Endocrinol Metab. 1996 May;81(5):1989-93.
* Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system
and its inhibitors. Recent development and its perspective in
treating androgen-dependent skin disorders. Dermatology. 1996;193(3):177-84.
* Ciotta L, Cianci A, Calogero AE, Palumbo MA, Marletta E, Sciuto
A, Palumbo G. Clinical and endocrine effects of finasteride,
a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism.
Fertil Steril. 1995 Aug;64(2):299-306.
* Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA.
A prospective randomized trial comparing finasteride to spironolactone
in the treatment of hirsute women. J Clin Endocrinol Metab.
1995 Jan;80(1):233-8.
* Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini
D, Bellotti G, Muggeo M. Clinical and hormonal effects of the
5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.
J Clin Endocrinol Metab. 1994 Oct;79(4):1115-21.
* Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of
finasteride, a 5 alpha-reductase inhibitor, on circulating androgens
and gonadotropin secretion in hirsute women. J Clin Endocrinol
Metab. 1994 Sep;79(3):831-5.
------------------------------------------------------------------------
Drug induced hypertrichosis references
* Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V,
Ryffel B. The side-effects of ciclosporine-A and tacrolimus.
Clin Nephrol. 1998 Jun;49(6):356-63.
* Yamamoto S, Kato R. Hair growth-stimulating effects of cyclosporin
A and FK506, potent immunosuppressants. J Dermatol Sci. 1994
Jul;7 Suppl:S47-54.
* Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced
hair loss and hair growth. Incidence, management and avoidance.
Drug Saf. 1994 Apr;10(4):310-7.
* Ozdogan M, Gur G, Kadayifcilar S, Boyacioglu S, Ozgur O, Teletar
H. An unusual adverse effect of interferon: hypertrichosis of
the eyelashes. J Interferon Cytokine Res. 2000 Jul;20(7):633-4.
* O'Connell BM, Abel EA, Nickoloff BJ, Bell BJ, Hunt SA, Theodore
J, Shumway NE, Jacobs PH. Dermatologic complications following
heart transplantation. J Heart Transplant. 1986 Nov-Dec;5(6):430-6.
* Berglund EF, Burton GV, Mills GM, Nichols GM. Hypertrichosis
of the eyelashes associated with interferon-alpha therapy for
chronic granulocytic leukemia. South Med J. 1990 Mar;83(3):363.
* Miwa LJ, Shaefer MS, Stratta RJ, Wood RP, Langnas AM, Shaw
BW Jr. Drug-induced hypertrichosis: case report and review of
the literature. DICP. 1990 Apr;24(4):365-8.
* Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis
during treatment with 5% topical minoxidil. Br J Dermatol. 1997
Jan;136(1):118-20.
* Baral J. Minoxidil and tail-like effect. Int J Dermatol. 1989
Mar;28(2):140.
* Kaler SG, Patrinos ME, Lambert GH, Myers TF, Karlman R, Anderson
CL. Hypertrichosis and congenital anomalies associated with
maternal use of minoxidil. Pediatrics. 1987 Mar;79(3):434-6.
* Schropl F. [Clinical studies with prednicarbate with special
reference to double-blind comparisons with common therapeutic
preparations]. Z Hautkr. 1986;61 Suppl 1:80-7.
* Robertson DB, Maibach HI. Topical corticosteroids. Int J Dermatol.
1982 Mar;21(2):59-67.
* Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br
J Dermatol. 1979 Nov;101(5):593-5.
* Earhart RN, Ball J, Nuss DD, Aeling JL. Minoxidil-induced
hypertrichosis: treatment with calcium thioglycolate depilatory.
South Med J. 1977 Apr;70(4):442-3.
* Lutz G. Effects of cyclosporin A on hair. Skin Pharmacol.
1994;7(1-2):101-4.
* Sever PS. Hypertrichosis and verapamil. Lancet. 1991 Nov 9;338(8776):1215-6.
* Gaffney CC, Roberts JT. Hypertrichosis lanuginosa acquisita
following cytotoxic chemotherapy. Clin Oncol (R Coll Radiol).
1992 Jul;4(4):267-8.
* Menter MA. Hypertrichosis lanuginosa and a lichenoid eruption
due to diazoxide therapy. Proc R Soc Med. 1973 Apr;66(4):326-7.
* Milner RD, Chouksey SK. Effects of fetal exposure to diazoxide
in man. Arch Dis Child. 1972 Aug;47(254):537-43.
hair removal
facts
for consumers
= recommended only for in-depth researchers